Publications
Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94.
Michalowska MM, Herholz K, Hinz R, Amadi C, McInnes L, Anton-Rodriguez JM, Karikari TK, Blennow K, Zetterberg H, Ashton NJ, Pendleton N, Carter SF. Mol Psychiatry. 2022 Oct;27(10):4335-4342. doi: 10.1038/s41380-022-01685-6. Epub 2022 Jul 20.
Investigating the use of plasma pTau181 in retired contact sports athletes.
Vasilevskaya A, Taghdiri F, Multani N, Ozzoude M, Tarazi A, Khodadadi M, Wennberg R, Rusjan P, Houle S, Green R, Colella B, Blennow K, Zetterberg H, Karikari T, Mikulis D, Hazrati LN, Kovacs GG, Davis KD, Tator C, Tartaglia MC. J Neurol. 2022 Oct;269(10):5582-5595....
Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease.
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD,...
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease.
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD,...
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases.
Snellman A, Lantero-Rodriguez J, Emeršič A, Vrillon A, Karikari TK, Ashton NJ, Gregorič Kramberger M, Čučnik S, Paquet C, Rot U, Zetterberg H, Blennow K. Brain. 2022 Aug 27;145(8):2834-2848. doi: 10.1093/brain/awab481.
Plasma p-tau181 shows stronger network association to Alzheimer’s disease dementia than neurofilament light and total tau.
Frank B, Ally M, Brekke B, Zetterberg H, Blennow K, Sugarman MA, Ashton NJ, Karikari TK, Tripodis Y, Martin B, Palmisano JN, Steinberg EG, Simkina I, Turk KW, Budson AE, O'Connor MK, Au R, Goldstein LE, Jun GR, Kowall NW, Stein TD, McKee AC, Killiany R, Qiu WQ, Stern...
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, Balls-Berry J, Bateman RJ, Xiong C, Zetterberg H, Blennow K, Morris JC. Neurology. 2022 Jul...
Comorbidities confound Alzheimer’s blood tests.
Schindler SE, Karikari TK. Nat Med. 2022 Jul;28(7):1349-1351. doi: 10.1038/s41591-022-01875-3.
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.
Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, Lantero-Rodriguez J, Pascoal TA, Suárez-Calvet M, Rosa-Neto P, Blennow K, Zetterberg H. Nat Rev Neurol. 2022 Jul;18(7):400-418. doi: 10.1038/s41582-022-00665-2. Epub 2022 May 18.
Editorial: Blood Biomarkers of Neurodegenerative Diseases.
Karikari TK, Ashton NJ, Zetterberg H, Blennow K. Front Mol Neurosci. 2022 Jun 30;15:966139. doi: 10.3389/fnmol.2022.966139. eCollection 2022.
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease.
Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simrén J, Vanmechelen E, Armstrong NJ, Hone E, Asih PR, Taddei K, Doré V, Villemagne VL, Sohrabi HR, Zetterberg H, Masters CL, Blennow K, Martins RN. Alzheimers Dement. 2022...
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging.
Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, Servaes S, Benedet AL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Kunach P, Wang YT, Fernandez-Arias J, Massarweh G, Vitali P, Soucy JP, Saha-Chaudhuri P, Blennow K, Zetterberg H, Gauthier S,...
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease.
Kac PR, Gonzalez-Ortiz F, Simrén J, Dewit N, Vanmechelen E, Zetterberg H, Blennow K, Ashton NJ, Karikari TK. Alzheimers Res Ther. 2022 May 11;14(1):65. doi: 10.1186/s13195-022-01011-w.
Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change.
Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simrén J, Lantero-Rodriguez J, Karikari TK, Hiniker A, Rissman RA, Salmon DP, Galasko D. Acta Neuropathol. 2022 Apr;143(4):487-503. doi: 10.1007/s00401-022-02408-5. Epub 2022 Feb 23.
Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, Vanmechelen E, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S;...
A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer’s disease.
Brum WS, de Bastiani MA, Bieger A, Therriault J, Ferrari-Souza JP, Benedet AL, Saha-Chaudhuri P, Souza DO, Ashton NJ, Zetterberg H, Pascoal TA, Karikari T, Blennow K, Rosa-Neto P, Zimmer ER; Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (N Y)....
The accuracy and robustness of plasma biomarker models for amyloid PET positivity.
Benedet AL, Brum WS, Hansson O; Alzheimer’s Disease Neuroimaging Initiative; Karikari TK, Zimmer ER, Zetterberg H, Blennow K, Ashton NJ. Alzheimers Res Ther. 2022 Feb 7;14(1):26. doi: 10.1186/s13195-021-00942-0.
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease.
Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, Mathotaarachchi S, Therriault J, Savard M, Chamoun M, Stoops E, Francois C, Vanmechelen E, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Rosa-Neto P. EBioMedicine. 2022 Feb;76:103836. doi:...
![Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET.](https://karikarilab.org/wp-content/uploads/2022/02/Comparing-tau-status-determined-via-plasma-pTau181-pTau231-and-18FMK6240-tau-PET-400x250.jpg)
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET.
Tissot C, Therriault J, Kunach P, L Benedet A, Pascoal TA, Ashton NJ, Karikari TK, Servaes S, Lussier FZ, Chamoun M, Tudorascu DL, Stevenson J, Rahmouni N, Poltronetti NM, Pallen V, Bezgin G, Kang MS, Mathotaarachchi SS, Wang YT, Fernandez Arias J, Ferreira PCL,...
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, Blennow K, Zetterberg H, Aarsland D; European–Dementia With Lewy Bodies (E-DLB)...
Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.
Gerards M, Schild AK, Meiberth D, Rostamzadeh A, Vehreschild JJ, Wingen-Heimann S, Johannis W, Martino Adami P, Onur OA, Ramirez A, Karikari TK, Ashton NJ, Zetterberg H, Blennow K, Maier F, Jessen F. Dement Geriatr Cogn Disord. 2022;51(2):182-192. doi:...
Blood Tests for Alzheimer’s Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.
Karikari TK. J Alzheimers Dis. 2022;90(3):967-974. doi: 10.3233/JAD-215730.
P-tau235: a novel biomarker for staging preclinical Alzheimer’s disease.
Lantero-Rodriguez J, Snellman A, Benedet AL, Milà-Alomà M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Karikari TK, Gispert JD, Salvadó G, Shekari M, Toomey CE, Lashley TL, Zetterberg H, Suárez-Calvet M, Brinkmalm G, Rosa Neto P, Blennow K. EMBO Mol Med. 2021...
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Salvadó G, Shekari M, Operto G, Gispert JD, Minguillon C, Fauria K, Kollmorgen G, Suridjan I,...
Prodromal frontotemporal dementia: clinical features and predictors of progression.
Benussi A, Ashton NJ, Karikari TK, Alberici A, Saraceno C, Ghidoni R, Benussi L, Zetterberg H, Blennow K, Borroni B. Alzheimers Res Ther. 2021 Nov 15;13(1):188. doi: 10.1186/s13195-021-00932-2.
Truncating tau reveals different pathophysiological actions of oligomers in single neurons.
Hill E, Karikari TK, Lantero-Rodriguez J, Zetterberg H, Blennow K, Richardson MJ, Wall MJ. Commun Biol. 2021 Nov 4;4(1):1265. doi: 10.1038/s42003-021-02791-x.
Publisher Correction: Microglial activation and tau propagate jointly across Braak stages.
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, Ottoy J, Mathotaarachchi S, Stevenson J, Massarweh G, Schöll M, de Leon MJ, Soucy JP, Edison P, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P. Nat Med....